Skip to main content

Table 2 Model input-data

From: Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany

 

Base-case

DSA

PSA

 

HZ

PHN

HZ

PHN

 

Epidemiology[21]

Age-group

Cases/1,000 PY

% of HZ-cases

95% CI (Cases/1,000 PY)

95% CI (% of HZ-cases)

Triangular

50–59

6.56

3.38

6.12–7.01

2.15–4.61

 

60–69

9.19

4.92

8.68–9.71

3.73–6.11

 

70–79

11.24

7.85

11.66–11.82

6.48–9.23

 

>80

12.76

7.8

11.92–13.61

6.05–9.55

 

Vaccine efficacy (%)[29, 30, 50, 51]

Age-group

  

95% CI

95% CI

Beta

50–59

69.8

65.7*

54.1–80.6

20.4*–86.7*

 

60–64

65.4

65.7

55–70.9

20.4–86.7

 

65–69

62.58

65.7

55–70.9

20.4–86.7

 

70–74

43.74

66.8

25–48.1

43.3–81.3

 

75–79

36.51

66.8

25–48.1

43.3–81.3

 

80–84

20.09

66.8

25–48.1

43.3–81.3

 

>85

13.22

66.8

25–48.1

43.3–81.3

 

EQ-5D utilitiesª[14]

Age-group

  

95% CI

95% CI

Beta

50–60

0.68

0.725

0.61–0.745

0.63–0.815

 

61–70

0.6

0.68

0.525–0.67

0.605–0.76

 

>70

0.62

0.64

0.550.69

0.57–0.705

 

Treatment costs per case (€)[21]

Perspectives/Age-group

Payer

Societal

Payer

Societal

Payer 95% CI

Societal 95% CI

Payer 95% CI

Societal 95% CI

Gamma

50–59

193

570

872

1,339

148–245

495–651

289–1,940

436–3,065

 

60–69

226

338

1,349

2,137

179–270

281–397

714–2,125

975–3,625

 

70–79

203

214

1,172

1,218

159–252

169–263

717–1,785

750–1,863

 

>80

320

331

642

676

249–394

259–408

251–1,157

270–1,207

 
 

Background mortality [probability (%) p.a.]***[48]

HZ related mortality [deaths/100,000 PY]***[22]

Age-group

         

50–59

  

0.7

   

0.02

  

60–69

  

1.5

   

0.09

  

70–79

  

3.9

   

0.42

  

80–89

  

11

   

2.53

  

90–99

  

26.2

   

3.86

  

100+

  

56.8

   

3.86

  

Other input parameter

 

Base-case

DSA [lower/higher value]

PSA

Vaccine Price/dose (€)[59]

140.48

70.24

210.72

Normal

Vaccine administration costs (€)**

7

5.20

10.81

Normal

Discount rate (% p.a.)

3

0

10

 

Waning immunity rate (% p.a.)[56]

8.3

0

20

Beta

Coverage (%) assumption

20

-

-

 

HZ susceptibility**** (%)[2]

100

-

-

 

EQ-5D utilities for healthy individuals (age in years)

1(all ages)

0.859b (41–60)

0.7684b (61+)

 
  1. DSA Deterministic Sensitivity Analysis, PSA Probabilistic Sensitivity Analysis displays the age related probability distribution of respective input-data used in Monte Carlo simulations, CI confidence interval, *value adopted from age 60; **vaccine administration costs adopted from pneumococcal vaccination (adjusted from different regional values); ***Values adjusted to table’s age-groups; ****All individuals in the model were susceptible for developing HZ due to high seroprevalence of varicella-zoster virus in the German population; ªAdjusted from Drolet et al. [14]; bGender unspecific values adjusted from linear model in Hinz et al. [61]; €, Euro in 2010 price levels; PY persons per year.